H S Sader - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

H S Sader

Showing results (51-60 of 100) with videos related to

Pageof 10

Sort By:

Revista Da Associacao Medica Brasileira (1992)|April 1, 1997

[Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria]A C Gales, A C Pignatari, R N Jones, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 24, 2017

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)R E Mendes, H S Sader, J I Smart, et al.

Journal of Chemotherapy (Florence, Italy)|September 25, 2023

Oritavancin <i>in vitro</i> activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010-2019)M A Pfaller, R E Mendes, H S Sader, et al.

Infection Control and Hospital Epidemiology|May 1, 1993

Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology studyH S Sader, A C Pignatari, R J Hollis, et al.

Journal of Chemotherapy (Florence, Italy)|December 1, 1996

In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolatesA C Gales, H S Sader, S Sinto, et al.

Journal of Chemotherapy (Florence, Italy)|December 3, 2010

Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infectionsM A Pfaller, P R Rhomberg, H S Sader, et al.

Diagnostic Microbiology and Infectious Disease|May 5, 2000

Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998)M T Lewis, A C Gales, H S Sader, et al.

Journal of Chemotherapy (Florence, Italy)|May 17, 2011

Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countriesJ E Ross, D J Farrell, R E Mendes, et al.

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|April 6, 2001

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance studyH S Sader, R N Jones, C H Ballow, et al.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2001

Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance programM A Pfaller, J Acar, R N Jones, et al.

Pageof 10

Search research articles

Showing results (51-60 of 100) with videos related to

Sort By:

Pageof 10

Revista Da Associacao Medica Brasileira (1992)|April 1, 1997

[Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria]A C Gales, A C Pignatari, R N Jones, et al.

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 24, 2017

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)R E Mendes, H S Sader, J I Smart, et al.

Journal of Chemotherapy (Florence, Italy)|September 25, 2023

Infection Control and Hospital Epidemiology|May 1, 1993

Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology studyH S Sader, A C Pignatari, R J Hollis, et al.

Journal of Chemotherapy (Florence, Italy)|December 1, 1996

In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolatesA C Gales, H S Sader, S Sinto, et al.

Journal of Chemotherapy (Florence, Italy)|December 3, 2010

Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infectionsM A Pfaller, P R Rhomberg, H S Sader, et al.

Diagnostic Microbiology and Infectious Disease|May 5, 2000

Journal of Chemotherapy (Florence, Italy)|May 17, 2011

Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countriesJ E Ross, D J Farrell, R E Mendes, et al.

The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|April 6, 2001

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2001

Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance programM A Pfaller, J Acar, R N Jones, et al.

Pageof 10